Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07291037 · ClinicalTrials.gov registry record · Phase 3

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

A Phase 3 study of Non-small Cell Lung Cancer (NSCLC), sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
400
Enrollment target
20
Study locations

NCT07291037: Recruiting Phase 3 study of Non-small Cell Lung Cancer (NSCLC), sponsored by AstraZeneca.

NCT07291037 is a Phase 3 study of Non-small Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 400 participants, above the 278-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (44% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07291037, a Phase 3 study of Non-small Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
400 participants
Enrollment target
20
Study locations

Study Summary

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

Primary Outcome

PFS is defined as the time from randomization until radiological progression per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR), or death due to any cause.

Conditions Studied

Non-small Cell Lung Cancer (NSCLC)

Interventions

  • DRUG Docetaxel
  • DRUG Datopotamab deruxtecan (Dato-DXd)

Study Locations (20)

California

  • Research Site - Duarte
  • Research Site - Irvine
  • Research Site - La Jolla
  • Research Site - Loma Linda
  • Research Site - Los Angeles
  • Research Site - San Diego

Florida

  • Research Site - Fort Myers
  • Research Site - Jacksonville
  • Research Site - St. Petersburg
  • Research Site - Tampa
  • Research Site - West Palm Beach

Arizona

  • Research Site - Chandler
  • Research Site - Gilbert
  • Research Site - Goodyear

Colorado

  • Research Site - Grand Junction
  • Research Site - Wheat Ridge

Georgia

  • Research Site - Marietta
  • Research Site - Newnan

Delaware

  • Research Site - Newark

District of Columbia

  • Research Site - Washington D.C.

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2025-10-31
Est. Completion 2029-01-29
Phase Phase 3
AstraZeneca

1,285 total trials

What NCT07291037 shows while recruiting

NCT07291037 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 278-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (44% higher).

The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.

NCT07291037 names 20 study sites across 7 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT07291037 about?

NCT07291037 is a clinical study titled "Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations". TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

What is the current status of trial NCT07291037?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2025-10-31. Estimated completion is 2029-01-29.

What conditions does trial NCT07291037 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).

What interventions are being tested in trial NCT07291037?

The interventions under investigation include: Docetaxel (DRUG), Datopotamab deruxtecan (Dato-DXd) (DRUG).

Who is sponsoring clinical trial NCT07291037?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07291037 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07291037's enrollment target sits among peer trials

400 15th of 59 higher than 45 of 59 other Non-small Cell Lung Cancer (NSCLC) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07291037

Source: ClinicalTrials.gov NCT07291037, the US trial registry maintained by the National Library of Medicine. NCT07291037 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.